^
HER-2 positive
HER2 Positive Breast Cancer
MAM-06.301
Sensitive
:
D
Cancer Cell Int - 1 week - (New D)
No biomarker
Triple Negative Breast Cancer
XMT-1660
Sensitive
:
B
Mersana Therapeutics Press Release - 2 weeks - (New B)
CDKN2A overexpression
Estrogen Receptor Positive Breast Cancer
CDK6 inhibitor
Resistant
:
D
Nat Commun - 2 weeks - (New D)
CDKN2A overexpression
Estrogen Receptor Positive Breast Cancer
CDK4 inhibitor
Resistant
:
D
Nat Commun - 2 weeks - (New D)
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pyrotinib
Sensitive
:
B
ESMO 2022 - 3 weeks - (New B)
HR positive
HER2 Negative Breast Cancer
dalpiciclib
Sensitive
:
B
ESMO 2022 - 3 weeks - (New B)
ER positive
HER2 Negative Breast Cancer
RAD1901
Sensitive
:
B
ESMO 2022 - 3 weeks - (New B)
HER-2 expression
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BRCA2 mutation + HR positive
HER2 Negative Breast Cancer
niraparib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BRCA1 mutation + HR positive
HER2 Negative Breast Cancer
niraparib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HR positive
HER2 Positive Breast Cancer
trastuzumab + abemaciclib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PTEN mutation
Breast Cancer
TAS-117
Sensitive
:
C4
ESMO 2022 - 3 weeks - (New C4)
BRCA1 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive
:
A1
AstraZeneca Press Release - 4 weeks - (New A1)
BRCA2 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive
:
A1
AstraZeneca Press Release - 4 weeks - (New A1)
PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + tucatinib
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
margetuximab
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
No biomarker
Breast Cancer
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive
:
A1
No biomarker
Breast Cancer
TAC
Sensitive
:
A1
HR positive
HER2 Positive Breast Cancer
neratinib
Sensitive
:
A1
HR positive
HER2 Negative Breast Cancer
palbociclib
Sensitive
:
A1
HR positive
HER2 Negative Breast Cancer
ribociclib
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
pertuzumab / trastuzumab / hyaluronidase-zzxf
Sensitive
:
A1
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
alpelisib
Sensitive
:
A1
HR positive
HER2 Negative Breast Cancer
abemaciclib
Sensitive
:
A1
PD-L1 expression
Triple Negative Breast Cancer
pembrolizumab
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-qyyp
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-qyyp
Sensitive
:
A1
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab-qyyp
Sensitive
:
A1
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab-qyyp
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-dttb
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-dttb
Sensitive
:
A1
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab-dttb
Sensitive
:
A1
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab-dttb
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-dkst
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-dkst
Sensitive
:
A1
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab-dkst
Sensitive
:
A1
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab-dkst
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-anns
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-anns
Sensitive
:
A1
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab-anns
Sensitive
:
A1
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab-anns
Sensitive
:
A1